Digest Network How does it work
Network
/
Society
Ex
Not verified

Exicure, Inc.

What we write about

BiotechnologyHealthMedicine - variousPharmaceuticalsScienza

24 Press releases

View all press releases
08/08/2025
Scienza
Sanità
Pharmaceuticals
Oncology
Psychiatry
Biotechnology
Medicine - various
Biology
Health
stock market
Exicure, Inc. Reports Second Quarter 2025 Financial Results
Source
Exicure, Inc.
Issuer
Business Wire
1.00
0
04/08/2025
Health
Biotechnology
Medicine - various
Scienza
Pharmaceuticals
Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements
Source
Exicure, Inc.
Issuer
Business Wire
1.00
0
01/08/2025
Scienza
Food hygiene
Biotechnology
Medicine - various
Health
Pharmaceuticals
Oncology
Industria
Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant
Source
Exicure, Inc.
Issuer
Business Wire
1.00
0
27/06/2025
Biotechnology
Sanità
Health
Biology
Pharmaceuticals
stock market
Exicure, Inc. Reports First Quarter 2025 Financial Results
Source
Exicure, Inc.
Issuer
Business Wire
1.00
0
28/05/2025
Scienza
Biotechnology
Medicine - various
Biology
Sanità
Health
Oncology
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q
Source
Exicure, Inc.
Issuer
Business Wire
1.00
0
05/05/2025
Industria
Scienza
Food hygiene
Medicine - various
Sanità
Biotechnology
Pharmaceuticals
Health
Oncology
Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant
Source
Exicure, Inc.
Issuer
Business Wire
1.00
0
14/04/2025
Industria
Scienza
Food hygiene
Medicine - various
Sanità
Biotechnology
Pharmaceuticals
Health
Oncology
Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma
Source
Exicure, Inc.
Issuer
Business Wire
1.00
0
11/04/2025
Industria
Scienza
Medicine - various
Biotechnology
Sanità
Health
Pharmaceuticals
Oncology
Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)
Source
Exicure, Inc.
Issuer
Business Wire
1.00
0
18/03/2025
stock market
Biotechnology
Pharmaceuticals
Health
Exicure, Inc. Reports Full Year 2024 Financial Results
Source
Exicure, Inc.
Issuer
Business Wire
1.00
0
13/03/2025
Oncology
Health
Medicine - various
Scienza
Pharmaceuticals
Biotechnology
Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia
Source
Exicure, Inc.
Issuer
Business Wire
1.00
0

Contact details

Social Media

Followers
0
Compatibility
0